Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KALV

KalVista Pharmaceuticals Inc

Dec 05 • 04:00PM ET

16.43

+0.03 0.18 %

Healthcare • Biotechnology • USA • NASD

Dec 03, 12:04 PMPositive Phase 3 data from HAE rival Pharvaris validated the oral treatment space, lifting shares as first-mover.

Peers: FATE RARE CORT QURE VKTX VSTM PVLA CYPH XERS XBIO

| Held by: VTI IWM XBI IWO VXF IBB LFSC SCHA VTWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.00	Insider Own	25.25%	Shs Outstand	50.54M	Perf Week	13.55%
Market Cap	830.48M	Forward P/E	18.05	EPS next Y	0.91	Insider Trans	-1.19%	Shs Float	37.78M	Perf Month	49.50%
Enterprise Value	803.90M	PEG	-	EPS next Q	-	Inst Own	97.72%	Short Float	38.26%	Perf Quarter	2.94%
Income	-203.10M	P/S	580.76	EPS this Y	87.71%	Inst Trans	5.25%	Short Ratio	10.13	Perf Half Y	14.38%
Sales	1.43M	P/B	48.85	EPS next Y	300.74%	ROA	-97.71%	Short Interest	14.45M	Perf YTD	93.98%
Book/sh	0.34	P/C	2.69	EPS next 5Y	-	ROE	-190.18%	52W High	17.28 -4.92%	Perf Year	68.86%
Cash/sh	6.12	P/FCF	-	EPS past 3/5Y	-3.17% -17.63%	ROIC	-68.88%	52W Low	7.30 125.07%	Perf 3Y	204.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-9.33%	Volatility	11.61% 8.18%	Perf 5Y	-12.19%
Dividend TTM	-	EV/Sales	562.17	EPS Y/Y TTM	-13.14%	Oper. Margin	-14220.90%	ATR (14)	1.05	Perf 10Y	-66.37%
Dividend Ex-Date	-	Quick Ratio	7.21	Sales Y/Y TTM	-	Profit Margin	-14242.57%	RSI (14)	71.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.22	EPS Q/Q	-1.45%	SMA20	20.68%	Beta	-0.15	Target Price	31.00
Payout	-	Debt/Eq	16.62	Sales Q/Q	-	SMA50	33.96%	Rel Volume	1.32	Prev Close	16.40
Employees	270	LT Debt/Eq	16.34	Earnings	Nov 11 BMO	SMA200	29.59%	Avg Volume	1.43M	Price	16.43
IPO	Apr 09, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.49% 99.78%	Trades		Volume	1,886,397	Change	0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$19
Jan-07-25	Initiated	TD Cowen	Buy	$30
Dec-18-24	Initiated	BofA Securities	Buy	$22
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks) +11.87%
Dec-03-25 04:09PM	Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment (Investor's Business Daily) +8.43%
Nov-18-25 06:16AM	Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects (Insider Monkey)
Nov-11-25 04:02PM	KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... (GuruFocus.com) +5.33% +16.30%
Nov-10-25 05:45PM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Loading…
04:30PM	KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results (Business Wire)
Nov-06-25 08:01AM	KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting (Business Wire)
Nov-05-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 (Business Wire)
Oct-30-25 07:00AM	KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (Business Wire)
Oct-06-25 04:00PM	KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe (Business Wire) -7.51%
07:00AM	KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer (Business Wire)
Oct-03-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-02-25 07:00AM	KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors (Business Wire)
Sep-26-25 07:00AM	KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 20th German Allergy Congress (Business Wire)
10:52PM	Loading…
Sep-24-25 10:52PM	KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 (Business Wire) -6.46%
04:01PM	KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes (Business Wire)
Sep-19-25 07:00AM	KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema (Business Wire) -5.12%
Sep-12-25 09:00AM	Morning Movers: Kroger rises following second quarter results (TipRanks) -5.40%
03:01AM	KalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ... (GuruFocus.com)
Sep-11-25 08:05AM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results (Business Wire)
04:55AM	Adobe earnings on tap as stock badly lags the broader market (MarketWatch)
04:13AM	Stock Market Today: S&P 500 and Nasdaq hold record highs, Dow near peak, as AI excitement lingers and investors hope CPI inflation data will confirm Fed rate cut trajectory. (MarketWatch)
Sep-04-25 07:05AM	KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025 (Business Wire) +7.34%
07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-25 02:00PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
07:00AM	KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-11-25 04:05PM	Metagenomi Appoints Laurence Reid, PhD to its Board of Directors (GlobeNewswire)
07:00AM	KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union (Business Wire)
07:00AM	Loading…
Aug-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-25 01:31AM	KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency (Insider Monkey)
Jul-25-25 08:00AM	KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks (Business Wire) -6.54%
Jul-15-25 04:05PM	KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
07:00AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results (Business Wire)
Jul-09-25 08:16AM	KalVista price target raised to $37 from $22 at BofA (TipRanks) +6.96%
Jul-08-25 07:00AM	DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat) (PR Newswire)
Jul-07-25 06:09PM	KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment (Investor's Business Daily) +25.71%
11:34AM	Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat) (PR Newswire)
06:37AM	US FDA approves KalVista's oral swelling disorder drug, shares rise (Reuters)
06:30AM	KalVista Pharmaceuticals Announces FDA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jul-02-25 04:05PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 06:03PM	Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada (PR Newswire)
07:00AM	KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada (Business Wire)
Jun-20-25 08:03AM	How KalVista Pharma Is Taking On A Rare But Deadly Disease (Investor's Business Daily)
Jun-18-25 09:31AM	FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use (Clinical Trials Arena)
Jun-16-25 07:00AM	KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis (Business Wire)
05:00AM	FDA to miss approval deadline for Kalvista drug due to resource constraints (BioPharma Dive)
Jun-13-25 04:05PM	KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints (Business Wire)
Jun-05-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 (Business Wire)
Jun-03-25 04:01PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-02-25 07:00AM	KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management (Business Wire) +9.49%
May-29-25 07:00AM	KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-22-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings (Business Wire)
May-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-30-25 07:00AM	KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference (Business Wire) +5.28%
Apr-12-25 12:42AM	KalVista: Poised For Rare Disease Transformation (Seeking Alpha)
Apr-08-25 10:27AM	KalVista licenses commercialisation rights for HAE to Kaken in Japan (Pharmaceutical Technology) -10.26%
06:30AM	KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan (Business Wire)
Apr-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-31-25 07:00AM	KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 11:14AM	KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial (Clinical Trials Arena)
Mar-25-25 07:00AM	KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial (Business Wire)
Mar-12-25 07:00AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire)
Mar-10-25 07:00AM	KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema (Business Wire)
Mar-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-25 07:00AM	KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-24-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire) -5.73%
Feb-10-25 07:00AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.75%
Jan-21-25 07:00AM	KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema (Business Wire) +5.42%
Jan-08-25 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.94%
Dec-16-24 07:00AM	KalVista Appoints Jeb Ledell as Chief Operating Officer (Business Wire)
Dec-05-24 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-24 07:00AM	KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors (Business Wire)
Nov-12-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-05-24 07:29AM	KalVista Secures $184M Financing for Sebetralstat Launch (TipRanks)
06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-24 07:05AM	KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million (Business Wire) +9.61%
07:00AM	KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust (Business Wire)
Oct-28-24 06:30AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology (Business Wire)
Oct-18-24 06:30AM	KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) (Business Wire)
Oct-04-24 12:29PM	KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum (Business Wire)
Oct-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 06:30AM	KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -6.16%
Sep-26-24 06:30AM	KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) (Business Wire) +5.71%
Sep-10-24 07:00AM	KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (Business Wire) -5.56%
06:30AM	KalVista Appoints Brian Piekos as Chief Financial Officer (Business Wire)
Sep-06-24 06:30AM	KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 (Business Wire)
Sep-05-24 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-03-24 06:30AM	KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -7.62%
Aug-29-24 06:30AM	KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium (Business Wire)
Aug-15-24 06:30AM	KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema (Business Wire)
Aug-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-11-24 02:52PM	KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sweeny Nicole	Chief Commercial Officer	Nov 24 '25	Sale	13.45	3,813	51,289	39,728	Dec 04 04:02 PM
Piekos Brian	Chief Financial Officer	Nov 24 '25	Sale	13.45	4,471	60,139	10,529	Nov 26 06:50 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 24 '25	Sale	13.45	4,331	58,256	223,508	Nov 26 06:49 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 24 '25	Sale	13.45	5,296	71,236	131,831	Nov 26 06:47 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 24 '25	Sale	13.45	10,940	147,154	416,189	Nov 26 06:46 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 20 '25	Option Exercise	0.00	87,390	376	220,964	Nov 21 04:07 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Sale	14.48	4,466	64,665	403,879	Nov 19 04:13 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 18 '25	Sale	14.48	2,683	38,848	133,574	Nov 19 04:11 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 18 '25	Sale	14.48	3,075	44,524	125,877	Nov 19 04:11 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 12 '25	Sale	11.55	3,328	38,438	398,981	Nov 13 04:28 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Sep 08 '25	Sale	15.84	7,294	115,537	395,189	Sep 09 07:02 PM
Sweeny Nicole	Chief Commercial Officer	Aug 25 '25	Sale	13.42	1,480	19,862	32,291	Aug 26 08:00 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 25 '25	Sale	13.42	1,954	26,223	132,052	Aug 26 07:59 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 25 '25	Sale	13.42	2,336	31,349	122,505	Aug 26 07:57 PM
Sweeny Nicole	Chief Commercial Officer	Aug 22 '25	Sale	13.22	1,864	24,647	28,771	Aug 25 09:33 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 22 '25	Sale	13.22	2,362	31,232	130,881	Aug 25 07:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 22 '25	Sale	13.22	10,940	144,657	386,858	Aug 25 07:46 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 22 '25	Sale	13.22	2,942	38,901	119,841	Aug 25 07:45 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 18 '25	Sale	13.19	2,649	34,932	129,493	Aug 19 04:27 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 18 '25	Sale	13.19	2,939	38,757	116,533	Aug 19 04:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 18 '25	Sale	13.19	4,409	58,141	374,548	Aug 19 04:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jul 09 '25	Sale	15.69	32,979	517,523	369,595	Jul 10 08:56 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Jul 09 '25	Sale	15.69	30,250	474,698	127,939	Jul 10 08:50 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 09 '25	Sale	14.50	7,169	103,950	315,074	Jun 10 05:00 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 23 '25	Sale	11.31	2,146	24,272	113,026	May 27 04:06 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 23 '25	Sale	11.31	1,926	21,782	98,189	May 27 04:05 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 22 '25	Sale	11.88	2,689	31,933	110,172	May 23 04:26 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 22 '25	Sale	11.88	2,317	27,516	96,990	May 23 04:25 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 22 '25	Sale	11.88	9,999	118,743	306,618	May 23 04:24 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 19 '25	Sale	11.84	2,600	30,791	95,557	May 20 07:28 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 19 '25	Sale	11.84	3,808	45,097	293,367	May 20 07:28 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 19 '25	Sale	11.84	2,776	32,876	106,611	May 20 07:27 PM
Venrock Healthcare Capital Par	10% Owner	Apr 09 '25	Buy	9.42	25,000	235,500	5,303,985	Apr 11 05:22 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Mar 07 '25	Sale	11.97	6,669	79,828	287,811	Mar 10 06:43 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	10.02	2,394	23,988	102,940	Feb 25 08:37 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 24 '25	Sale	10.02	1,918	19,218	93,952	Feb 25 08:36 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 18 '25	Sale	9.82	2,601	25,553	92,745	Feb 19 08:47 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	9.82	3,125	30,701	100,334	Feb 19 08:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	9.82	5,104	50,143	278,855	Feb 19 08:46 PM
Venrock Healthcare Capital Par	10% Owner	Feb 12 '25	Buy	9.23	100,000	923,000	5,217,285	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 13 '25	Buy	9.33	61,700	575,661	5,278,985	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 07 '25	Buy	9.29	73,649	684,199	5,086,445	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 11 '25	Buy	9.18	26,703	245,134	5,117,285	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 10 '25	Buy	9.14	4,137	37,812	5,090,582	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Jan 30 '25	Buy	8.76	43,707	382,873	4,986,480	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 03 '25	Buy	9.22	14,562	134,262	5,012,796	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Jan 31 '25	Buy	8.89	11,754	104,493	4,998,234	Feb 03 07:42 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	9.75	7,627	74,363	274,596	Dec 09 09:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KALV

KalVista Pharmaceuticals Inc

Upgrade your FINVIZ experience